Suggestions
Christopher Kim
Director, Observational Research (Epidemiology/real world evidence) at Amgen
Professional Background
Christopher Kim is a distinguished epidemiologist currently leading a dedicated team at Amgen in the Center for Observational Research (CfOR). In this role, he focuses on hematologic malignancies and drives Real World Evidence (RWE) studies that aim to address unmet medical needs within the community. His expertise includes providing context for single-arm clinical trials through the identification of external historical control groups, which play a critical role in enhancing the validity of research studies. Additionally, Christopher designs post-marketing commitment studies (PMC/PMR) and critically evaluates risk management minimization plans (RMM/RMP) to ensure drug safety and effectiveness after market authorization. His work also encompasses comparing the effectiveness of various drugs and treatment regimens, as well as identifying evolving treatment trends while contributing to a more profound understanding of the epidemiology of various diseases.
Before joining Amgen, Christopher honed his skills and knowledge as a post-doctoral fellow at the National Institutes of Health (NIH) within the National Cancer Institute's Division of Cancer Epidemiology and Genetics. This experience provided him with invaluable insight into the complexities of cancer research and further cemented his passion for improving public health through data-driven evidence.
With a progressive career trajectory, Christopher has held several influential roles at Amgen, initially joining as a Manager in the Observational Research (Epidemiology) team. His expertise and leadership abilities propelled him to Senior Manager and ultimately to his current position as Director. In each of these roles, he has successfully managed various research projects, contributing significantly to the field of epidemiology and the advancement of Public Health.
Education and Achievements
Christopher's academic journey is marked by a solid foundation in the sciences, beginning with his Bachelor of Arts in Biology from Boston University. He further developed his expertise in epidemiology by obtaining a Master of Public Health (MPH) with a focus on Epidemiology and Environmental Health at the same institution. However, it was at Yale University where he earned his Doctor of Philosophy (PhD) in Epidemiology and Public Health, diving deeply into research that has poised him as a leading figure in the sector.
Throughout his career, Christopher has been a part of various prestigious organizations that reflect his commitment to public health and epidemiology. He takes pride in his work during his time at Brookline Health Department as a Program Coordinator, where he played a role in promoting health initiatives within the community. Additionally, his experience as a Research Assistant at the Boston University School of Public Health further equipped him with real-world skills necessary for conducting high-quality research and analysis.
Contributions and Impact
In his current role at Amgen, Christopher Kim significantly impacts the landscape of drug development and cancer research through observational studies. His dedication to understanding the real-world effectiveness of drug therapies and developing comprehensive risk management plans is essential in addressing the evolving public health challenges in hematologic malignancies. By leveraging RWE studies, he provides crucial insights that can guide healthcare providers, policymakers, and industry leaders in making informed decisions that ultimately enhance patient outcomes.
His effort to analyze treatment trends and identify unmet needs in the community is of paramount importance in the development of innovative treatment options. Christopher's background in epidemiology not only influences the types of studies conducted but also helps lay the groundwork for developing new molecules and therapies post-marketing authorization.
Christopher's academic and professional achievements exemplify a robust commitment to advancing public health through rigorous epidemiological research. He continually seeks collaborations with various stakeholders to ensure that the research is actionable and applicable in real-world settings. His journey is a testament to the symbiotic relationship between academia and industry, showcasing how evidence-based research can transform patient care and improve health outcomes.
Achievements
- Director and leader of the Observational Research (Epidemiology) team at Amgen, focusing on real-world evidence studies for hematologic malignancies.
- Key player in the design and execution of post-marketing safety commitment studies, contributing to the safety profiles of new therapies.
- Extensive experience with evaluating the effectiveness and comparative analysis of drugs, significantly aiding in treatment decision-making processes.
- Holds an influential post-doctoral fellowship at the National Institutes of Health, enriching expertise in cancer epidemiology;
- Strong educational background with a PhD in Epidemiology and Public Health from Yale University, enhancing his analytical capabilities in the field.
- Recognition and involvement in the development of impactful health initiatives during his tenure at the Brookline Health Department.
- Proven track record of research as evidenced by his role as a Research Assistant at the Boston University School of Public Health.
